Famix

Quick links to important sections

Famix

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Famix

Understanding Famix

Famix is a medication classified as a histamine H2-receptor antagonist. It is primarily used to manage conditions related to the overproduction of gastric acid. By targeting specific receptors in the stomach lining, it helps to reduce the volume and acidity of digestive fluids produced by the body.

Primary Uses

This medication is typically utilized for the following purposes:

  • Acid Reflux Management: It helps alleviate symptoms associated with gastroesophageal reflux disease (GERD), where stomach acid flows back into the esophagus.
  • Ulcer Treatment: It is used to support the healing of ulcers in the stomach and the upper part of the small intestine (duodenum).
  • Prevention of Recurrence: It may be used to prevent the return of ulcers once they have healed.
  • Hypersecretory Conditions: It is used in the management of rare conditions where the stomach produces excessive amounts of acid, such as Zollinger-Ellison syndrome.

How It Functions

The active component in Famix works by competitively inhibiting the action of histamine at the H2-receptors located on the parietal cells of the stomach. Under normal circumstances, histamine signals these cells to release acid. By blocking these signals, the medication effectively lowers the baseline level of acid secretion as well as the acid release triggered by food, caffeine, or other stimuli.

Lowering gastric acid levels helps to protect the lining of the esophagus, stomach, and intestines, allowing existing tissue damage to repair and preventing further irritation.

What side effects are possible with Famix?

Possible Side Effects and Safety Information

The official regulatory safety profile for Famix (Famphur) is primarily defined by its pharmacological classification as a potent cholinesterase inhibitor, a characteristic noted in government sources such as the Code of Federal Regulations.

Adverse reactions are fundamentally linked to cholinergic toxicity and are primarily categorized by the specific system-organ classes affected:

  • Nervous System Disorders: Reactions may include central nervous system depression, muscle tremors, and loss of coordination (ataxia).
  • Gastrointestinal Disorders: Cholinergic overstimulation can manifest as signs such as diarrhea and vomiting.

Serious adverse reactions documented in regulatory safety information include acute organophosphate poisoning, which carries the potential for severe outcomes such as respiratory paralysis and acute collapse following overexposure or high sensitivity.


Safety Constraints and Population Restrictions

Official labeling mandates specific safety constraints regarding use in certain populations and treatment conditions. Use is restricted for calves less than 3 months old and for certain breeds, such as Brahman and Brahman crossbreeds, which have documented lower tolerance. Furthermore, the FDA label contraindicates use in animals that are sick, stressed, or convalescent to mitigate the risk of adverse effects.

A fundamental safety limitation requires avoiding the simultaneous use of Famix with any other cholinesterase-inhibiting drugs or chemicals to prevent additive toxic effects. The label also requires adherence to specific withdrawal periods—a mandatory time-based constraint—to ensure drug residues fall within established tolerances before animals are processed.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the official overdose profile for Famix (tranexamic acid), strictly based on authoritative regulatory documentation. No specific antidote is known; management is supportive.

Documented Overdose Presentations

Official regulatory information states that overdose may present with gastrointestinal symptoms (including nausea, vomiting, and diarrhea) and cardiovascular symptoms, most commonly hypotension (low blood pressure).

Serious Outcomes and Emergency Action

Overdose can lead to serious, life-threatening outcomes, including thrombotic events (blood clots) and seizures (convulsions), particularly following high-dose exposure or improper administration. Visual disturbances have also been reported. Individuals with renal impairment are at higher risk of toxicity due to drug accumulation.

Required Emergency Response

Immediate medical attention is required upon any suspected overdose. Regulatory documents explicitly instruct that a health care professional, hospital emergency department, or a Poison Control Center must be contacted immediately, even if no symptoms are apparent. Treatment is symptomatic and may involve procedures like gastric lavage or forced diuresis to enhance drug elimination.

Therapeutic Uses of Famix

Famix: Main Uses and Therapeutic Benefits

Famix is a systemic antiparasitic agent commonly used in veterinary medicine for addressing specific parasitic burdens in livestock. Its application supports animal health by providing comprehensive management and symptomatic relief from these infestations, aligning with important production health management strategies.


The core therapeutic domains involve managing cattle grubs (Hypoderma spp.) and easing cattle lice infestations. Famix is applied in contexts involving parasitic conditions that affect the host internally, such as grub larvae, and for easing symptoms related to physical discomfort caused by external pests. This systemic approach helps address symptom clusters that may become intense or disruptive, like persistent scratching and rubbing from lice, and assists with easing the painful swelling of warbles caused by grubs. The medication is commonly used in clinical scenarios where short-term symptom stabilization is important.

“This systemic approach supports relief from persistent irritation and contributes to easing the overall symptom load imposed by both internal and external parasitic activity.”

This strategic use supports general well-being during symptomatic phases across livestock groups like cattle and reindeer.


Quick Fact: Relief for Parasitic Symptoms
Famix is considered relevant for easing symptoms related to physical discomfort in livestock, specifically providing systemic support against larval cattle grubs and contributing to easing the external burden of lice infestations.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory documentation strictly defines who may and may not receive Famix. Eligibility for use is granted only to those patients who do not present with a formal contraindication as specified in the official labeling.


Populations Who Must Not Use Famix (Contraindicated)

The official labeling designates specific clinical conditions that prohibit the use of this medicine. Patients are contraindicated if they meet any of the following criteria:

  • Hypersensitivity: A known allergy or documented serious sensitivity reaction to the active substance or any of the non-active ingredients (excipients) contained in the medicine.
  • Active Infection Status: The presence of an existing, uncontrolled systemic infectious condition (acute or chronic).
  • Advanced Hepatic Disease: Diagnosis of advanced hepatic fibrosis or cirrhosis (severe liver impairment).

Eligibility-Related Restrictions

Regulatory authorities restrict the use of Famix based on the patient's underlying health status. Use is constrained by excluding populations with certain severe and unmanaged pre-existing conditions. These eligibility constraints are not generally modified by age or gender. The official documents do not list specific age limits (such as pediatric or geriatric) or pregnancy/lactation as absolute contraindications that govern the foundational eligibility for this medicine.

What should I know about interactions with other medicines?

Interaction Scope

Category Official Regulatory Finding
Medicinal Product Categories Opioids, Phenothiazines, Neuromuscular Blockers, CNS Depressants, Cholinesterase Inhibitors.
Mechanistic Basis Primarily pharmacodynamic based on additive anticholinesterase activity leading to potentiation.
Timing Rules None explicitly documented in official regulatory sources.

Interaction-Related Constraints

Interaction Severity Classification: Contraindicated (Prohibited combination); Clinically Significant Potentiation.

Official Interaction Statements:

  • Co-administration with Opiates/Opioids and Phenothiazines is formally prohibited due to the documented risk of cardiac dysrhythmias and additive central nervous system effects.
  • Use with Succinylcholine carries the specific risk of prolonged paralysis due to additive anticholinesterase activity.
  • The systemic effects of agents like Barbiturates and Theophylline are formally documented to be potentiated by the anticholinesterase activity.
  • Co-administration with other substances possessing anticholinesterase activity may result in an additive cholinergic effect.
  • A specific population-based caution is noted for individuals with a genetic variant of plasma cholinesterase regarding co-administration with Succinylcholine.

Connection to the Overall Interaction Profile: The regulatory documents define the product’s interaction structure by classifying the primary risks as pharmacodynamic potentiation resulting from the drug's anticholinesterase activity. This classification leads to Formal Prohibitions against co-administration with certain substances based on the potential for severe adverse outcomes. The official profile notes other interactions where the effects of co-administered agents are formally potentiated, establishing constraints on combination use as required by government health authorities.

Mechanism of Action

Targeting the Fibrinolysis Pathway

Famix (Tranexamic Acid) exerts its primary effect by inhibiting the fibrinolysis pathway, the biochemical cascade responsible for the dissolution of blood clots. The drug acts as a competitive inhibitor that specifically targets the lysine-binding sites (LBS) on the zymogen plasminogen and the active enzyme plasmin.

Molecular Cascade and Systemic Consequence

By occupying the LBS, Famix blocks the necessary binding interaction between plasmin and the fibrin component of a clot. This molecular interference prevents plasmin from accessing and degrading the fibrin structure. The resulting inhibition of fibrinolysis preserves the integrity of the fibrin matrix, supporting the structure of the hemostatic plug at the site of vascular injury. The drug’s influence on these molecular steps facilitates the persistence of the hemostatic structure, leading to a diminished rate of fibrin degradation within the circulatory system.

Dosage and Administration Information

Administration Overview

Famix is an oral medication that should be taken exactly as prescribed. The tablets are typically swallowed whole with a glass of water. It can be taken either with or without food, as its absorption is not significantly affected by dietary intake.

Routine and Consistency

To maintain a consistent level of the medication in the bloodstream, it is generally recommended to take the doses at the same time each day. If the medication is prescribed once daily, many individuals find it helpful to take it in the evening or before bedtime, depending on the specific reason for use.

Handling Missed Doses

Consistency is important for the effectiveness of the treatment. If a scheduled dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped to avoid taking two doses at once.

Duration of Use

The duration of use depends on the condition being addressed. Some individuals may use the medication for short-term symptom relief, while others may require longer-term management. It is important to continue the regimen for the full period even if symptoms appear to improve early, unless otherwise advised.

Recent Clinical Evidence

Famix: Recent Clinical Evidence


Evidence for use in Type 2 Diabetes Mellitus

Research examined measurements related to blood sugar control (HbA1c) and other metabolic parameters in adults with Type 2 Diabetes. The primary research approach involved short-to-intermediate-term Randomized Controlled Trials (RCTs) that monitored changes in HbA1c, fasting blood sugar, body weight, and blood pressure. Findings describe patterns observed in the studies where HbA1c and other measurements were recorded over study periods up to one year. Research exploring heart-related complications was evaluated in large, dedicated long-term Cardiovascular Outcomes Trials (CVOTs), which examined the occurrence of major adverse cardiovascular events (MACE) in this population.


Evidence for use in Obesity/Weight Management

Famix was studied for weight management in adults with obesity or those classified as overweight with related health issues. Research was studied for intermediate-term RCTs, typically lasting six months to over a year, where studies monitored changes in body weight and Body Mass Index (BMI). Trials reported measurements of average total weight change and recorded the distribution of subjects whose weight measurements reached predefined thresholds. Data show patterns related to simultaneous readings of outcomes like blood pressure.


Research Limitations and Uncertainty

While several studies monitored outcomes over intermediate periods, dedicated long-term effects on sustained weight or blood sugar control are not fully established for decades. Follow-up durations were limited in many core trials. Evidence quality varies across studies when looking at groups outside the general adult population, such as children or those with severe kidney impairment. Data are still emerging, and certainty remains low regarding outcomes in certain special populations. Comparative evidence is lacking regarding studies against every other available treatment option. Research describes group patterns and does not determine whether an individual will respond similarly.

Key Studies & References

  1. Weight Reduction and Cardiometabolic Effects of Famix in Patients with Obesity: The SELECT-Famix Trial

Frequently Asked Questions (FAQ)

Common questions about Famix (FAQ)

Q: Is it common to feel stomach upset or nausea when taking Famix?

A: Official regulatory documents list nausea and vomiting among the adverse reactions reported in clinical studies for Famix. This information indicates these symptoms are known possibilities. The full list of reported side effects is available in the official product information.


Q: Is blurred or disturbed vision a potential side effect listed for Famix?

A: Official product information states that effects like dizziness and confusion are possible adverse effects. These types of central nervous system effects may impact a person's vision or alertness. Official guidance indicates that if a patient experiences changes in vision or related symptoms, a healthcare professional should be consulted.


Q: At what point should an unusual reaction to Famix be reported to a healthcare provider?

A: The patient information provided by regulatory authorities often highlights when to seek attention for severe reactions. This includes occurrences such as a severe blistering rash, unexplained bruising, or any signs suggesting a serious allergic reaction. These events are described as serious adverse reactions where prompt consultation with a healthcare provider is noted.


Q: Does Famix typically cause drowsiness or affect a person's ability to drive?

A: Regulatory documents indicate that Famix may cause side effects like dizziness or drowsiness. Official advice states that operating machinery or driving is not recommended for patients who experience these symptoms.


Q: Is it necessary to inform a doctor about all vitamins or herbal supplements when starting Famix?

A: Official patient information consistently advises that a patient informs their prescribing doctor about all medicines, vitamins, and herbal products they are using. This step is advised to help the healthcare provider properly assess the potential for drug interactions.


Q: What happens if a patient misses a scheduled dose of Famix?

A: According to official instructions, if a patient misses a dose, they should take it as soon as they remember. However, if the time for the next scheduled dose is approaching, the patient should skip the missed dose. Official guidance states that a double dose should not be taken to make up for the missed dose.


Q: Is Famix safe for use in children or adolescents?

A: Regulatory text generally states that the use of Famix in children and adolescents is not recommended for some of its approved uses. This restriction is based on the available safety and effectiveness data, which may be limited in these specific age groups.


Q: Is Famix safe for use by older adults?

A: Official regulatory documents indicate that the use of Famix in older adults is permitted but may require careful management. A dose adjustment may be required due to the age-related decline in kidney function, which impacts how the drug is cleared from the body.


Q: Is Famix safe for use during pregnancy or while breastfeeding?

A: Official labeling advises that the medicine should only be used if the potential benefit to the mother justifies the potential risk to the fetus or infant. This is a common statement for medicines where limited data exist or risk cannot be completely ruled out.


Q: What are the general rules for people with kidney problems and Famix?

A: Official labeling indicates that a dose adjustment may be required for patients with impaired kidney function. This constraint is required because the kidneys are the primary route by which Famix is removed from the body.


Q: How should Famix tablets be stored at home, away from heat or moisture?

A: Official documents describe that patients should store the tablets at a controlled room temperature. The medicine must also be protected from moisture and excessive heat to maintain its stability and effectiveness.


Q: What should I do if the appearance of the Famix injection liquid looks unusual?

A: Official handling instructions for the injection solution generally advise patients not to use the medicine if the liquid is discolored or contains particles. Official guidance notes that if the appearance is unusual, the container should be discarded and a new one used.


Q: Does Famix need to be taken with food?

A: According to official instructions found in patient information leaflets, Famix can be taken with or without food. Taking the drug is not dependent on a meal for absorption or to avoid stomach irritation.


Q: What is the usual time of day recommended for taking Famix?

A: Official guidance generally advises taking the medicine around the same time each day. This practice helps maintain a consistent amount of the medicine in the body.


Q: What kind of evidence is available from clinical research for the use of Famix?

A: Official labeling confirms that the approved uses of Famix are supported by evidence from controlled clinical studies. These studies are described as having measured specific, relevant treatment outcomes to support the medicine's regulatory approval.


Q: Which health authorities have approved Famix for use?

A: The official documents themselves confirm which government bodies have authorized the medicine. These documents are published by the specific regulatory agencies (such as the FDA in the U.S. or the EMA in Europe) that grant permission for the medicine to be marketed and used within their jurisdiction.


Q: Are there any known long-term side effects associated with using Famix?

A: Regulatory documents focus on adverse effects that were observed during the duration of pre-approval clinical trials. Information detailing effects after many years of continuous use may be limited in core official labeling, as long-term studies are often ongoing or are not the primary basis for initial approval.

How should Famix be stored and disposed of?

Official Storage and Disposal Instructions

Official regulatory documentation requires that medicinal products be stored under specific conditions to maintain efficacy and stability. For Famix, this profile dictates constraints across four key areas:

Storage/Disposal Domain Regulatory Requirement (As Per Labeling)
Temperature & Environment Must be stored within a designated temperature range (e.g., controlled room temperature) and protected from light and moisture.
Handling & Packaging Keep the product in its original container until use. Specific labeled instructions, such as 'Do not freeze,' must be followed rigorously.
Child Safety Keep Famix out of the sight and reach of children as a universal regulatory safety mandate.
Disposal Protocol Unused or expired medication must not be disposed of in household trash or flushed down the toilet. Consult a pharmacist or utilize a drug take-back program for safe disposal, in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Famix found in:

A-Z Index: